These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 9410098)

  • 41. New drug interactions with zidovudine.
    Robertson-Dallas S; Read SE; Bendayan R
    Pharmacotherapy; 1997; 17(6):1198-209. PubMed ID: 9399602
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development and significance of zidovudine resistance in children infected with human immunodeficiency virus.
    Ogino MT; Dankner WM; Spector SA
    J Pediatr; 1993 Jul; 123(1):1-8. PubMed ID: 8100579
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Persistence of Macrocytosis after Discontinuation of Zidovudine in HIV-Infected Patients.
    Yu I; Greenberg RN; Crawford TN; Thornton AC; Myint T
    J Int Assoc Provid AIDS Care; 2017; 16(5):512-515. PubMed ID: 28393661
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Zidovudine phosphorylation determined sequentially over 12 months in human immunodeficiency virus-infected patients with or without previous exposure to antiretroviral agents.
    Hoggard PG; Lloyd J; Khoo SH; Barry MG; Dann L; Gibbons SE; Wilkins EG; Loveday C; Back DJ
    Antimicrob Agents Chemother; 2001 Mar; 45(3):976-80. PubMed ID: 11181396
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anemia among HIV Infected Individuals Taking ART with and without Zidovudine at Addis Ababa, Ethiopia.
    Tamir Z; Alemu J; Tsegaye A
    Ethiop J Health Sci; 2018 Jan; 28(1):73-82. PubMed ID: 29622909
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Zidovudine-associated adverse reactions in a longitudinal study of asymptomatic HIV-1-infected homosexual males.
    Baum MK; Javier JJ; Mantero-Atienza E; Beach RS; Fletcher MA; Sauberlich HE; Feaster D; Shor-Posner G
    J Acquir Immune Defic Syndr (1988); 1991; 4(12):1218-26. PubMed ID: 1941528
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Eleven lymphoid phenotypic markers in HIV infection: selective changes induced by zidovudine treatment.
    Bass HZ; Hardy WD; Mitsuyasu RT; Wang YX; Cumberland W; Fahey JL
    J Acquir Immune Defic Syndr (1988); 1992; 5(9):890-7. PubMed ID: 1512689
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Exposure to zidovudine adversely affects mitochondrial turnover in primary T cells.
    Wallace ZR; Sanderson S; Simon AK; Dorrell L
    Antiviral Res; 2016 Sep; 133():178-82. PubMed ID: 27496003
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Zidovudine-induced restoration of cell-mediated immunity to mycobacteria in immunodeficient HIV-infected patients.
    French MA; Mallal SA; Dawkins RL
    AIDS; 1992 Nov; 6(11):1293-7. PubMed ID: 1472334
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetic interactions of zidovudine and methadone in intravenous drug-using patients with HIV infection.
    Schwartz EL; Brechbühl AB; Kahl P; Miller MA; Selwyn PA; Friedland GH
    J Acquir Immune Defic Syndr (1988); 1992; 5(6):619-26. PubMed ID: 1588496
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term zidovudine reduces neurocognitive deficits in HIV-1 infection.
    Baldeweg T; Catalan J; Lovett E; Gruzelier J; Riccio M; Hawkins D
    AIDS; 1995 Jun; 9(6):589-96. PubMed ID: 7662198
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Peripheral nerve function in persons with asymptomatic or minimally symptomatic HIV disease: absence of zidovudine neurotoxicity.
    Bozzette SA; Santangelo J; Villasana D; Fraser A; Wright B; Jacobsen C; Hayden E; Schnack J; Spector SA; Richman DD
    J Acquir Immune Defic Syndr (1988); 1991; 4(9):851-5. PubMed ID: 1654410
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Zidovudine for asymptomatic HIV patients?].
    Flepp M
    Dtsch Med Wochenschr; 1994 Oct; 119(40):1374-5. PubMed ID: 7924945
    [No Abstract]   [Full Text] [Related]  

  • 54. The clinical significance of the biological phenotype of HIV.
    Lange JM; de Jong MD
    AIDS Clin Rev; 1993-1994; ():1-18. PubMed ID: 8217894
    [No Abstract]   [Full Text] [Related]  

  • 55. An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. Delta Coordinating Committee and Virology Group.
    AIDS; 1999 Apr; 13(5):565-73. PubMed ID: 10203381
    [TBL] [Abstract][Full Text] [Related]  

  • 56. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
    AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
    Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Frequency and characteristics of patients treated with zidovudine and absence of progression of HIV infection].
    Soriano V; Heredia A; Mas A; Vallejo A; Garćia-Lerma G; Bravo R; Gómez-Cano M; Villalba N; Moreno V; Laguna F; Valencia E; Martínez P; González-Lahoz J
    An Med Interna; 1997 Jun; 14(6):282-5. PubMed ID: 9410098
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.